Clinical trial • Phase III • Other
GRT6019
Phase III trial of GRT6019. 24 participants.
Overview
- Trial Therapeutic Area
- Other
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 09-10-2025
- First CTIS Authorization Date
- 19-12-2025
Trial design
Phase III trial across 1 site in France.
- Target Sample Size
- 24
Eligibility
Recruits 24 No vulnerable population selected; trial includes healthy male participants only; no specific consent or assent handling described..
- Vulnerable Population
- No vulnerable population selected; trial includes healthy male participants only; no specific consent or assent handling described.
Recruitment
- Planned Sample Size
- 24
- Recruitment Window Months
- 6
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 24
France
- Earliest CTIS Part Ii Submission Date
- 26-11-2025
- Latest Decision Or Authorization Date
- 19-12-2025
- Processing Time Days
- 23
- Number Of Sites
- 1
- Number Of Participants
- 24
Sites
- Site Name
- Biotrial
- Department Name
- Unité Clinique
- Contact Person Name
- Marina Klein
- Contact Person Email
- marina.klein@biotrial.com
Sponsor
Primary sponsor
- Full Name
- Gruenenthal GmbH
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Germany
Investigational products
- Investigational Product Name
- GRT6019
Related trials
Other published trials that may interest you.